Treats cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM). Sold as Attruby. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Acoramidis Hydrochloride (sold as Attruby), first approved Nov 22, 2024, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Attruby | Part D | $406M | +46531% | 3,546 |
| Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisTransthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis · Eidos Therapeutics, a BridgeBio company | Phase 4 | Recruiting | Jul 10, 2026 |
| Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac BiomarkersTransthyretin-type Cardiac Amyloidosis · Alexion Pharmaceuticals, Inc. | Phase 4 | Recruiting | Dec 29, 2025 |
| To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial · Eidos Therapeutics, a BridgeBio company | Phase 3 | Not yet recruiting | Aug 11, 2025 |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantAmyloidosis, Amyloid Cardiomyopathy · Eidos Therapeutics, a BridgeBio company | Phase 3 | Recruiting | Aug 21, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 22, 2024 | AttrubyNDA 216540 · New molecular entity | Bridgebio Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
